Washington Court Ruling Mandates Coverage for GLP-1 Weight Management Medications
Washington state insurers are now prohibited from implementing blanket refusals to cover GLP-1 medications for weight management, following a recent decision by the Washington Court of Appeals. Historically, insurance companies have been reluctant to include coverage for weight-loss medications, often citing the historical lack of efficacy and high cost associated with these treatments. However, the introduction of GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro—initially approved for managing diabetes—offers a new therapeutic avenue by enhancing insulin regulation and moderating appetite.
The recent court ruling requires insurance providers in Washington to justify decisions on excluding specific weight-loss medications, aligning with the state's legal framework that recognizes obesity as a disability. An earlier Supreme Court ruling in 2019 established obesity as a legally protected condition, safeguarding against discrimination on this basis. Judge Ian Birk emphasized that health plans cannot exclude treatment for a disability without a valid reason, dismissing longstanding exclusion practices for these specific drugs.
The ongoing court case stems from Jeannette Simonton's lawsuit against her insurance provider, following their denial of coverage for the obesity medication she required before undergoing knee surgery. Despite receiving coverage for bariatric surgery and nutritional counseling, her plan did not include prescription drugs for obesity management, such as GLP-1s. This situation reflects common exclusions still observed in the insurance industry.
Pharmacoeconomic expert Joey Mattingly predicts that exclusionary practices for weight-loss medications like GLP-1s will diminish as these treatments demonstrate increasing efficacy and decreasing costs. Mattingly foresees potential shifts in employer-provided coverage as more data supports these medications’ benefits.
Despite the favorable court ruling, Simonton continues to pay out-of-pocket for her prescribed medication, citing the financial strain it imposes. Her case challenges the rationale behind denying insurance coverage for medically necessary treatments like weight-loss drugs, particularly when related to recognized disabilities.
The decision's implications extend beyond obesity-related treatments. As highlighted by Emily Brice of the Northwest Health Law Advocates, the ruling could influence similar exclusions for other recognized disabilities, potentially affecting coverage for services such as mental health care and hearing aids. The decision aligns with a broader effort to ensure equitable healthcare coverage for individuals with disabilities under Washington law.